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The second edition of Drug Policy and the Public Good presents up-to-date evidence relating to the 
development of drug policy at local, national, and international levels.  The book explores both illicit 
drug use and nonmedical use of prescription medications from a public health perspective.  The core 
of the book is a critical review of the scientific evidence in five areas of drug policy: 1) primary 
prevention programs in schools and other settings; 2) treatment interventions and harm reduction 
approaches; 3) attempts to control the supply of illicit drugs, including drug interdiction and law 
enforcement; 4) penal approaches, decriminalization and other alternatives; and 5) control of the 
legal market through prescription drug regimes.  It also discusses the trend toward legalization of 
some psychoactive substances in some countries and the need for a new approach to drug policy 
that is evidence-based, realistic, and coordinated.  The accumulated evidence provides important 
information about effective and ineffective policies.  Shifting the emphasis toward a public health 
approach should reduce the extent of illicit drug use, prevent the escalation of new epidemics, and 
avoid the unintended consequences arising from the marginalization of drug users through severe 
criminal penalties. 
 




This article is protected by copyright. All rights reserved. 
Introduction: Framing the Issues  
 
The use of psychoactive substances is commonplace in many parts of the world, despite the best 
efforts of policymakers, government officials, public health advocates, and concerned citizens to 
prevent, eliminate, or control it. If the last century's experience can serve as a guide, in the future 
many countries will face periodic drug use epidemics followed by aggressive policy responses to 
suppress them. These policy responses, or more specifically, the scientific evidence on the impact of 
policy, constitute the core interest of the second edition of the book, Drug Policy and the Public 
Good [1].  In this article, we summarize the main themes of the book, and at the same time put our 
review of the global drug situation in context by reflecting on areas that the book may not have 
covered because the science base was inadequate or the topics were too speculative. 
 
Matters of substance 
 
Psychoactive substances vary tremendously in their pharmacological properties, cultural symbolism, 
and reinforcing effects.  Advances in neuroscience and other disciplines have improved our 
understanding of how drugs affect neurotransmitters, behavior, and the adverse consequences of 
acute as well as chronic use. Whether a particular drug is natural or synthetic, for example, affects 
its portability and abuse potential.  Another important distinction is related to the way in which it is 
ingested.  Substances that can be smoked, inhaled or snorted reach the brain rapidly and tend to 
have strong reinforcing effects.  Drugs that can be diluted and then injected into the bloodstream 
provide more rapid delivery, which greatly increases their abuse potential.  
 
Implicit in the development of intervention programs and prevention strategies is the notion that 
some drugs are more risky or harmful than others, and as such may merit more control, resources 
and monitoring.  Legal substances like tobacco and alcohol have always generated aggregate harm 
at least as great as illicit substances like heroin and cocaine, in part because legal availability 
facilitates widespread use, but more recent trends have shown the complicated interplay between 
the black, grey, and legal markets for opioids [2].  And even substances with lower risk for 
dependence like cannabis can cause considerable harm if they are used with high frequency, 
intensity, and prevalence [3, 4]. 
 
Any consideration of the public health impact of psychoactive substances therefore needs to take 
into account three important mechanisms of harm: the physical toxicity of the substance, the 
intoxicating effects it produces, and its potential for creating drug dependence.  Figure 1 illustrates 
how the risks associated with psychoactive substances vary according to the drug’s mode of 
administration, drug dose, and use patterns.  These mechanisms mediate the consequences of drug 
use and suggest that the chemical substance itself, in its pure form, is only one among many factors 
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Drug use in global perspective 
 
The United Nations estimates that 5% of the world population, or a quarter of a billion people 
between the ages of 15 and 64, used an illicit drug at least once in 2014 [5]. Cannabis in its various 
forms is the most widely used illicit substance.  Surveys suggest that the proportion of the 
population who report ever having used an illicit drug (in the range of 10– 50%) is 6 to 15 times 
higher than the proportion who report symptoms of current drug dependence [6], in part because 
most people who try a drug never proceed to regular use.  The risk of dependence is considerably 
higher for those who use on an ongoing basis. Of the 247 million people who report using drugs in 
the past year, an estimated 29 million (11.5%) had drug use disorders [5]. From 2006 to 2014 the 
global annual prevalence of illicit drug use remained fairly stable at around 5%, and a similar trend is 
observed for problem drug use, being around 0.6% [5].  
 
There are significant differences in the extent of drug use and associated problems across countries 
and regions of the world. These differences at the population level reflect variations in drug markets, 
drug availability, and legislation as well as political, economic, and social conditions. Cultural and 
historical conditions can also play an important role. 
 
Increases in drug use and in problems related to production and trafficking have been particularly 
marked in regions going through major political and societal changes.  Another trend in a few 
countries (e.g. the United States, Canada, and Australia) has been for increased non-medical use of 
psycho-pharmaceutical drugs [7, 8], particularly opioid analgesics. Excessive prescribing of 
prescription opioids and subsequent attempts to restrict that prescribing are thought to have 
triggered an increase in the use of illicit heroin in North American, especially heroin that is 
adulterated with fentanyl or other synthetic opioids.  This is reflected in sharp increases in deaths 
related to these drugs over the past decade [9]. 
 
There is overwhelming evidence from epidemiological research conducted over the past 50 years 
that youth is the period of greatest risk for the initiation of drug use [10, 11].  Problem drug users 
are more often males and are likely to have a family history of substance dependence, delinquent 
behavior and mental health problems. To the extent that drug use is most often interwoven in a 
complex network of other social problems, both at the individual level and at the societal level, 
strategies to prevent drug use or drug related harms need to be cognizant of this complexity. 
 
Harms associated with illicit drug use  
 
Five types of morbidity and mortality have been identified as primary expressions of health harm 
associated with illicit drug use: 1) overdose; 2) other injury; 3) non-communicable physical disease; 
4) mental disorders, including drug dependence; and 5) infectious disease.  In 2017, 585,000 deaths 
and 41,700 thousand disability-adjusted life years lost were estimated to have been caused by illicit 
drug use [12]. Both estimates show a considerable increase from 1990 and steady increase over the 
past decade [13, 12].   
 
Although the burden, harm, and costs attributable to illicit drug use are substantial, especially in 
high income countries [12], for most nations they are markedly lower than those attributable to 
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alcohol and tobacco.  However, drug-related harm may in certain historical situations become a key 
factor in life expectancy reversals for countries, such as in the recent declines in life expectancy in 
the US or in Mexico [14, 15].   
 
Opioids, cocaine, and amphetamines entail greater risks, especially when they are injected. As 
suggested in Figure 1, many harmful consequences are not necessarily intrinsic to the properties of 
the drug, but instead are associated with the physical and social environment in which drug use 
takes place.  A society’s drug policy will be more likely to meet its chosen goals if these 
epidemiological considerations about the distribution of harms are taken into account in the 
allocation of resources for prevention, treatment, and social service programs [16]. 
 
Illegal markets: the economics of drug distribution and social harm  
 
Illegal drugs are commodities that are bought and sold in markets.  These markets differ in terms of 
their organizational form, pricing strategies, product quality and degree of associated corruption.  
Internet-enabled, direct to consumer sales are increasing for certain new psychoactive substances, 
and also for cannabis in some legal markets.  Nevertheless, with the notable exception of fentanyl, 
most drug harms stem from substances with more traditional supply chains.  Many farmers are 
engaged in small amounts of drug growing in the producing countries, but there are comparatively 
small numbers of refiners, smugglers, and top-level importers.  Compared to most legal markets, 
there are many sellers relative to the number of buyers in drug markets.  
 
Despite the belief that drug markets are dominated by a small number of cartels, syndicates and 
organized crime families, drugs are produced and distributed by the collective efforts of millions of 
individuals and small organizations that operate in a highly decentralized manner.  One consequence 
of the network character of drug distribution is its resilience.  Eliminating individual players or even 
entire organizations within a mature drug distribution network has little impact on the ability of the 
network as a whole to transport drugs from their source to the customers.  This adaptability of 
mature drug distribution networks limits the ability of enforcement authorities to eradicate mass-
market drugs.   
 
Illegal drugs are very expensive relative to legal drugs and most other familiar consumer goods. High 
prices reduce consumption, abuse, and adverse health-consequences, even for users who are drug 
dependent [17], but high prices tend to impoverish drug users, increase the amount of crime they 
commit, and enrich drug distributors [18].  Regarding quality, illicit drug markets deliver low-quality 
goods and services because of the absence of regulation and the inability to enforce contracts 
through normal means.  Adulteration and the lack of quality control can cause harm in many ways, 
including the risk of overdose.  Harms are not limited to individuals.  Production and trafficking are 
associated with corruption, political instability, violence and rates of addiction in both source and 
transit countries [19, 20].  Most of the market-related harms are a consequence of efforts to reduce 
drug use, especially the laws and programs prohibiting the production, distribution, and possession 
of illicit drugs, although the benefits of reduced use arising from prohibition may well override the 
market harms that prohibition creates.  Hence, the best response might be to reform prohibition, 
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The legal market: prescription and diversion of psychopharmaceuticals  
 
The growth of modern medicine is paralleled by substantial growth in psychopharmaceutical 
medications designed to treat psychiatric disorders, pain, cognitive dysfunction, mental distress, and 
sleep disorders. These medications, many of which have high dependence potential, are primarily 
distributed, at least in high-income countries, through a prescription system.  
 
Global consumption of pharmaceutical opioids has more than tripled over the past 20 years [21, 22], 
but the consumption of opioids for pain care is highly unbalanced between richer and poorer 
countries. For example, about 90% of the world’s morphine is consumed in a small number of 
countries (mostly the United States, Canada, Australia, New Zealand, and in Western Europe), 
whereas a large majority of the global population, mostly in low and middle income countries, have 
very limited access to opioid medications.  These differences in psychopharmaceutical use are 
driven, at least in part, by a combination of relative affluence, cultural factors, and the influence of 
pharmaceutical marketing [23, 24, 25]. The disparity is also related more to overconsumption in 
some countries (e.g., US and Canada), and to limited availability of psychopharmaceutical supplies in 
some lower-income countries, than to differences in mental distress or pain across countries. 
 
Diversion of psychopharmaceuticals from the prescription system for the purpose of non-medical 
use constitutes a substantial part of the illicit drug market in a growing number of countries.  While 
there is criminal or organized diversion from the prescription system as well as counterfeit products, 
most of the diversion happens informally, often at the consumer/patient end of the distribution 
chain. There is substantial evidence that ‘informal sourcing’ of prescription drugs from peers, 
friends, or family members constitutes the main pathway for a great part of non-medical use [26].  
 
A large amount of psychopharmaceuticals in unregulated markets are there as ‘diverted’ 
medications from legitimate production or from dispensing at different points of the health-care 
system. This includes large amounts of prescriptions written and dispensed at the retail level, 
whether based on deviant procurement practices like “doctor-shopping” or as legitimate 
prescriptions that are diverted within a legitimate care system. It is therefore no surprise that 
nations that dispense the largest amounts of these medications experience the most severe 
problems with regard to diversion and misuse [27, 2].  Although ‘medical use’ and ‘non-medical use’ 
of psychoactive medications are often assumed to be mutually exclusive categories, the pathways of 
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Strategies and interventions to reduce drug use and related harm  
 
Within the global prohibition framework, a variety of strategies and interventions have been 
developed to reduce illicit drug use and related harm.  The scientific evidence for these policy 
options is derived from a variety of research methods and measurement techniques, ranging from 
randomized clinical trials of prevention programs to “natural experiments” that evaluate the impact 
of new policies.  Contemporary drug policy is concentrated in three broad areas:  programs to 
prevent drug use, services that help heavy drug users change their behavior or the consequences of 
that behavior, and supply control programs.  In recent years, addiction science has matured as an aid 
to policy formation and evaluation.  Drawing on an extensive literature of both original research and 
integrative literature reviews, the remainder of this article summarizes the book’s critical evaluation 
of the scientific evidence relevant to each of these areas.  
 
Preventing illicit drug use by young people  
 
There is a broad array of options available within the ambit of youth-focused prevention, comprising 
both distinct strategies (e.g. mass media campaigns, community-based family strengthening 
programs) and many forms of school-based drug prevention.  Amongst the plethora of school, 
education and community based prevention programs, there is evidence that some approaches can 
delay the initiation of drug and alcohol use [28], particularly curricula that take a developmental and 
social skills approach by combining social competence and social influence components. 
 
A small number of high quality studies find evidence supporting specific family based or classroom 
management programs in preventing drug or alcohol use. It is notable that these programs do not 
focus exclusively or specifically on drug or alcohol use per se [28, 29].  Rather, their aim is to improve 
behaviour and social skills more generally, within the family or classroom environment.  These 
programs also show evidence of wider effect beyond drugs or alcohol.  In contrast, purely didactic 
prevention programs have no evidence of effectiveness, whether delivered through the mass media, 
in the community, or in the classroom. And other forms of primary prevention like drug testing in 
schools [30, 31] and  mass media campaigns on their own are not effective in preventing or reducing 
drug use by young people [32, 33].  
 
Health and social services for drug users  
 
Health and social services attempt to reduce drug-related harm by promoting abstinence, by 
reducing the frequency of drug use, and by changing behaviours that are harmful to drug users and 
society at large, such as injection drug use, drug overdose and criminal activity.  Among the most 
carefully evaluated programs are interventions focused on users of heroin and other opioids.  
Overall, Opioid Substitution Therapy (OST) has stronger evidence of effectiveness than any other 
intervention for opioid use disorder [34].  The documented benefits of OST include reduced 
overdose mortality, less HIV infection, and lower crime rates.  When fixed medium or high doses are 
used, buprenorphine and methadone are equally effective [35].  Naltrexone implants and depot 
formulations circumvent the major problem of poor adherence, with positive randomized clinical 
trials in USA, Russia, and Norway [36-40].  Good results have also been reported for supervised 
heroin substitution treatment for patients who repeatedly fail standard treatments [41]. 
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Therapeutic Communities (TCs) have also shown positive results in quasi- experimental studies [42, 
43].  Psychosocial interventions for users of cocaine, cannabis, methamphetamine, hallucinogens, 
benzodiazepines, and club drugs have evidence of effectiveness as well, with good evidence for 
reducing drug use, drug-related problems, and criminal activity, across a range of drugs and 
administration routes, and in both low income and high income countries [44, 45].  One very specific 
approach that has shown consistent effectiveness across a range of substance use disorders, 
populations, and settings is contingency management (e.g. ‘voucher based reinforcement’) [46].  
 
Harm reduction services directly target the specific risks of drug use (e.g., drug overdose deaths; 
infection or transmission of HIV or hepatitis B or C) without making the assumption that cessation of 
drug use needs to be a main therapeutic goal. There is evidence to support the effectiveness of 
needle exchange programs in reducing the transmission of HIV [47], and the pre-provision of take-
home naloxone has been found to save lives with a very low incidence of adverse events [48]. 
Supervised consumption sites, where drug users can inject or otherwise consume their drugs in a 
safe environment with medical assistance available, have a good record of reducing overdoses and 
other risks from use supervised in the facility [49].  
 
A range of treatments for addiction provide valuable contributions to the criminal justice system, 
often in the context of being alternatives to incarceration. Drug courts can reduce crime and 
promote treatment participation [50-52].  Drug treatment in prisons and after release helps 
prisoners remain abstinent, prevents recidivism, and facilitates continued employment, especially if 
OST or a TC model is used [53-55].  Evidence [56] also supports the benefits of mutual help 
organisations (e.g. Narcotics Anonymous and similar recovery programs).  
 
Countries differ markedly in terms of the availability, accessibility, coordination, cost-effectiveness, 
and coerciveness of treatment and harm reduction services [57]. However, treatment services alone, 
without coordination with criminal justice, health care, psychiatric services and social services, are 
unlikely to have an impact at the population level, as reflected in reduced rates of substance-related 
mortality and morbidity. However, in many low income countries, the treatment gap is more related 
to availability of services and lack of a health care infrastructure, than to the organization of the 
health system [58]. 
 
Supply control  
 
Supply control approaches to drug policy focus on constraining the production, distribution, and sale 
of illicit psychoactive substances, and include alternative development programs in producer 
nations, interdiction in transit zones and at national borders, control of precursor chemicals used to 
produce certain drugs (e.g., methamphetamines), and the arrest and incarceration of drug dealers at 
all market levels.  There is no evidence that promoting alternative economic and social development 
as part of global drug control strategy has a noticeable effect on drug use in the principal consuming 
countries.  Other interventions far up the distribution chain (e.g., crop eradication, interdiction, 
precursor controls) have produced transient market disruptions sufficient to affect drug use and 




This article is protected by copyright. All rights reserved. 
Figure 2 illustrates a supply-side success.  Between 2006 and 2010 the quantity of cocaine consumed 
in the United States declined by over 50% [60]. A wide variety of indicators (e.g. overdose deaths, 
treatment admissions) showed declines consistent with this trend.  While the estimated number of 
frequent users did decline by 20% over the period, it is likely that users also reduced their 
consumption.  Both could stem from price increases whose origins are not entirely clear, but may be 
due to some combination of a reduction in cocaine supply in Colombia, the effects of a crackdown 




Regarding the pursuit and punishment of high-level dealers, what little evidence exists suggests that 
there may be diminishing returns to drug policy goals from extended periods of incarceration.  
Finally, local or street-level enforcement is probably not an efficient strategy for reducing drug use, 
simply because the number of current and potential sellers is so large as to overwhelm the capacity 
of the criminal justice system to deliver punishment.  Supply-control interventions absorb the bulk of 
drug control spending in most nations, yet the evidence which would support these interventions is 
weak, in part because the existing evaluations fail to demonstrate effects on either the supply or the 
price of drugs in the marketplace.   
 
Criminalization and decriminalization of drug use or possession  
 
Research suggests that punishing drug users has limitations as a major component of drug policy 
[62].  An increasing number of countries and jurisdictions have therefore been reducing or 
eliminating criminal penalties for possession of small amounts of drugs for personal use, on grounds 
both of proportionality and effectiveness-oriented policy. Most decriminalization or depenalization 
programs involve the substitution of civil penalties for criminal penalties for possession offenses, 
while retaining full formal prohibition. The balance of the available evidence is that removing or 
reducing criminal penalties on possession does not lead to substantial increases in use [63].  For 
cannabis in particular, there are a number of cases where there was no measurable change in 
consumption from such a policy change [64, 65].  
 
Prescription regimes and other measures to control misuse of psychopharmaceuticals  
 
There is extraordinary global variation in the availability of prescription psychoactive drugs, with 
most prescription drug use being concentrated in developed countries.  A variety of measures aim to 
prevent abuses such as “doctor shopping” and diversion of psychopharmaceuticals from the medical 
and pharmacy systems. The evidence [66, 67] suggests that prescription regimes affect the 
prescribing practices of doctors, although restrictions often result in substitution of other 
medications which are sometimes equally or even more harmful. Price can be used to channel 
demand between two drugs that are substitutes for each other, moving demand from a drug with 
more adverse consequences to a less risky alternative [68, 27].  Advice to physicians on prescribing, 
in the absence of regulatory enforcement, has limited effect unless the advice concerns a new and 
serious side-effect and alternative medicines can be prescribed [69].  Shifting a prescribed drug onto 
a special prescription register, in conjunction with guidelines that limit prescriptions, reduces 
prescriptions of that drug [70]. In summary, the development of a strong pharmacy system can limit 
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illicit misuse of prescription medications, but in countries with a very high demand for 
psychopharmaceuticals, such systems have not been able to prevent periodic epidemics of 
prescription drug misuse. 
 
Drug policy and control at the international level  
 
International drug control efforts are designed to coordinate domestic laws with international 
activities that regulate or limit the supply of psychoactive substances.  At the heart of international 
drug policies are three UN drug control treaties adopted in 1961, 1971 and 1988, which, along with 
several UN bodies (e.g., Commission on Narcotic Drugs (CND), the International Narcotics Control 
Board (INCB), and the World Health Organization (WHO)), attempt to protect public health by 
ensuring the availability of useful drugs for medical and scientific purposes, while criminalizing illegal 
production and trade in order to prevent diversion and drug abuse.  The gross imbalance in world 
consumption of legal opiates is a pointer to the limited availability of effective pain medications in 
many low-income countries, with 80% of the world’s population having either no or inadequate 
access to treatment for moderate or severe pain [71].  Regarding the ability of the international drug 
control system to restrict illicit markets and supply, reports from the international agencies indicate 
that the drug problem continues to constitute a serious threat to the health, safety and well-being of 
humanity [72, 73].  With the proliferation of New Psychoactive Substances and the move by some 
countries to reconsider the prohibition of cannabis, there are several options which may be taken to 
modify the system, including: amendments to the conventions and rescheduling of cannabis.  
Nevertheless, drug policy and control at the international level remains a work in progress limited by the 
lack of consensus regarding effective methods and the challenges of emerging drug epidemics. 
 
Legalizing the supply of cannabis 
 
A fundamental policy question concerning any intoxicant is whether unsupervised use for 
recreational purposes—and production and supply of material for such use—ought to be legal or 
illegal. Changing the legal status of cannabis has attracted the most attention because of its 
widespread use and relatively favorable risk profile in comparison with several legal substances.  
Even as nations like Uruguay and Canada, and several subnational jurisdictions in the US, have 
legalized cannabis production and use, it is difficult to predict the effects of those actions because 
there is virtually no prior research on the topic.  The full effects of legalization will take a generation 
or more to manifest, and there are many different design options for legalization that will need to be 
evaluated.  Building on the writings of several authors [74-77, 60], it is possible to consider a 
spectrum of legalization alternatives, including home growing, cannabis clubs and government 
monopolies, that contrast with the commercial licensing system used to regulate alcohol in many 
countries and cannabis in some U.S. states and Canadian provinces.  A major challenge in setting up 
a legal regime for cannabis is to adopt an architecture for structuring the market that puts limits on 
availability and on promotion and marketing. It is also important for the system to be insulated from 
market interests, political pressures and from “regulatory capture”, which occurs when a regulatory 
agency, created to act in the public interest, instead pays too much attention to the commercial or 
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Conclusions and Reflections 
 
The main message of this book summary is that scientific research is available to inform the 
development and implementation of drug policy. Yet current drug policy in most societies takes 
limited account of this research. Among the 47 options reviewed in the book, most show some 
evidence of effectiveness in at least one country, but the evidence is less than definitive for many 
others, either because the interventions are ineffective, or the research is inadequate.  
Unfortunately, policies that have shown little or no evidence of effectiveness continue to be used in 
many countries and recommended by international organizations.   
 
The evidence supports two overarching conclusions that can guide future efforts to reduce the 
harmful effects of psychoactive substances.  First, an integrated and balanced approach to evidence-
informed drug policy is more likely to benefit the public good than are uncoordinated efforts to 
reduce drug supply and demand.  Second, by shifting the emphasis toward a public health approach, 
it may be possible to reduce the extent of illicit drug use, moderate the escalation of new epidemics, 
and avoid the unintended consequences arising from the marginalization of drug users through 
severe criminal penalties.  
 
In updating the contents of this book, the authors became increasingly aware of the public health 
challenges of illicit substances, manifested not only in the endemic nature of many drug problems, 
but also in the new epidemics that develop with technological innovations (e.g., New Psychoactive 
Substances, the spread of fentanyl, online markets).  In the policy arena, the reciprocal connections 
between the illicit drug market and the legal pharmaceutical industry in some of high-income 
countries require new models of empirical research and better theories to guide surveillance and 
policy at the population level.  In some respects, the disproportionate concentration of current drug 
research on neuroscience-derived, individual-level explanations and pharmacological interventions 
leaves a vacuum in funding for policy research directed at broader, population-level dynamics, such 
as the long-term effects, positive and negative, of decriminalization, cannabis legalization and the 
commercialization both of psychopharmaceutical and of recreational drug use.  Drug policy remains 
a work in progress that will require greater investment in a range of research strategies that are 
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Figure 1.  How toxic effects, intoxication and dependence are related to drug dose, use patterns and mode of 
drug administration, and in turn mediate the consequences of drug use for the individual drug user. 
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Fig. 2 Quantity of cocaine consumed in the United States, 2000– 2010.  











           
 
 
